We have investigated the clinical significance of the BRCA1 variant p.His1673del in 14 families from the Emilia-Romagna region of Italy, including 20 breast and 23 ovarian cancer cases; four families displayed site-specific ovarian cancer. The variant, absent in human variation databases, has been reported three times in BRCA1 specific databases; all probands shared the same rare haplotype at the BRCA1 locus, consistent with a common ancestor. The multifactorial likelihood method by Goldgar, used to estimate the probability of the variant being causative, gave a ratio of 2,263,474:1 in favor of causality. Moreover, in silico modeling suggested that His1673-lacking BRCA1 protein may have a decreased ability to bind BARD1 and other related pr...
Germline mutations in the BRCA1 and BRCA2 genes contribute to approximately 18% of hereditary ovaria...
In the Milan area (Northern Italy), we identified a family characterized by a high prevalence of ova...
Genome-wide studies of patients carrying pathogenic variants (mutations) in BRCA1 or BRCA2 have repo...
We have investigated the clinical significance of the BRCA1 variant p.His1673del in 14 families from...
BRCA1 germline mutations confer susceptibility to familial breast and ovarian cancer. Mutational hot...
The identification of founder mutations in cancer predisposing genes is important to improve risk as...
The heritable defects of BRCA1 and BRCA2 genes have been shown to predispose to breast and ovarian c...
BRCA1 germline mutations confer susceptibility to familial breast and ovarian cancer. Mutational hot...
A group of 103 sicilian patients with hereditary and familiar breast and/or ovarian cancer were scre...
We report a novel BRCA1 germline 4156delAA mutation detected in a 41-year-old woman with breast and ...
Genetic linkage studies have led to the identification of highly penetrant genes as the possible cau...
Genome-wide studies of patients carrying pathogenic variants (mutations) in BRCA1 or BRCA2 have repo...
PURPOSE: To evaluate the contribution of germline BRCA1 mutations in the incidence of hereditary and...
Germline point mutations in BRCA1 and BRCA2 genes account for about 30% of the inherited breast and ...
Double heterozygosity (DH) in BRCA1 and BRCA2 genes and double mutation (DM) in BRCA1 or BRCA2 are e...
Germline mutations in the BRCA1 and BRCA2 genes contribute to approximately 18% of hereditary ovaria...
In the Milan area (Northern Italy), we identified a family characterized by a high prevalence of ova...
Genome-wide studies of patients carrying pathogenic variants (mutations) in BRCA1 or BRCA2 have repo...
We have investigated the clinical significance of the BRCA1 variant p.His1673del in 14 families from...
BRCA1 germline mutations confer susceptibility to familial breast and ovarian cancer. Mutational hot...
The identification of founder mutations in cancer predisposing genes is important to improve risk as...
The heritable defects of BRCA1 and BRCA2 genes have been shown to predispose to breast and ovarian c...
BRCA1 germline mutations confer susceptibility to familial breast and ovarian cancer. Mutational hot...
A group of 103 sicilian patients with hereditary and familiar breast and/or ovarian cancer were scre...
We report a novel BRCA1 germline 4156delAA mutation detected in a 41-year-old woman with breast and ...
Genetic linkage studies have led to the identification of highly penetrant genes as the possible cau...
Genome-wide studies of patients carrying pathogenic variants (mutations) in BRCA1 or BRCA2 have repo...
PURPOSE: To evaluate the contribution of germline BRCA1 mutations in the incidence of hereditary and...
Germline point mutations in BRCA1 and BRCA2 genes account for about 30% of the inherited breast and ...
Double heterozygosity (DH) in BRCA1 and BRCA2 genes and double mutation (DM) in BRCA1 or BRCA2 are e...
Germline mutations in the BRCA1 and BRCA2 genes contribute to approximately 18% of hereditary ovaria...
In the Milan area (Northern Italy), we identified a family characterized by a high prevalence of ova...
Genome-wide studies of patients carrying pathogenic variants (mutations) in BRCA1 or BRCA2 have repo...